Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avdoralimab versus placebo in COVID-19 induced pneumonia
2020-001686-36Phase 2Completed
- Sponsor
- Assistance Publique-Hôpitaux de Marseille
- Start
- Apr 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in coronavirus pneumonia and coronavirus disease 2019 (COVID-19) comparing Avdoralimab with Placebo (2 arms). Primary endpoints: Clinical improvement on WHO Ordinal Scale at Day 14 and Clinical improvement on WHO Ordinal Scale at Day 28. Started Apr 2020; status: completed.
02
Drugs
avdoralimab
03
Conditions
coronavirus pneumoniacoronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-001686-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001686-36.